At the15th Anniversary Global Biotechnology Frontier Thousand Talents Conference held in freehand brushwork in 2020, a number of bio-enterprises to be listed in the future were announced, including Shenzhen Anmei Bio. Fund-raising and public offering are in full swing, and both of them are in prominent positions, indicating that the state has given the greatest support to the work of biotechnology enterprises, so Shenzhen Anmei Bio is eligible for listing.
Shenzhen Anmei Biotechnology Co., Ltd. has an expert team composed of strategic scientists, scientific and technological talents and high-skilled talents, focusing on the research and application of key core technologies and products in the fields of malignant tumors and autoimmune diseases, so as to improve national health awareness and reduce the incidence of cancer in China.